Wed, December 11, 2024
Tue, December 10, 2024
[ Tue, Dec 10th 2024 ]: The New Yorker
The Dawn of the Bionic Man
[ Tue, Dec 10th 2024 ]: Mercury News
California News
[ Tue, Dec 10th 2024 ]: ABC News
Entertainment News
Mon, December 9, 2024
[ Mon, Dec 09th 2024 ]: BBC
Beds, Herts & Bucks
[ Mon, Dec 09th 2024 ]: Uproxx
The Best TV Shows Of 2024
[ Mon, Dec 09th 2024 ]: Paste
The 25 Best PC Games of 2024
[ Mon, Dec 09th 2024 ]: CNET
Top News Stories
Sun, December 8, 2024
Sat, December 7, 2024
[ Sat, Dec 07th 2024 ]: Newsweek
Russia-Ukraine War
[ Sat, Dec 07th 2024 ]: imdb.com
Canada's 30 Funniest TV Shows
[ Sat, Dec 07th 2024 ]: Daily Mail
UK Celebrity News
[ Sat, Dec 07th 2024 ]: Food Safety News
Food Safety News
Fri, December 6, 2024
[ Fri, Dec 06th 2024 ]: Graphic
Latest Ghana News Headlines Today
[ Fri, Dec 06th 2024 ]: The Columbian
Clark County News
[ Fri, Dec 06th 2024 ]: who13
Cyclones react to 10 wins
[ Fri, Dec 06th 2024 ]: TravelPulse
Hotels and Resorts News
[ Fri, Dec 06th 2024 ]: Business Standard
Share Market Today
[ Fri, Dec 06th 2024 ]: Reuters
Aerospace & Defense
Thu, December 5, 2024
[ Thu, Dec 05th 2024 ]: Interest
All news stories
[ Thu, Dec 05th 2024 ]: Paste
The 30 Best TV Shows of 2024
[ Thu, Dec 05th 2024 ]: Phil Bruner
Featured News Stories
[ Thu, Dec 05th 2024 ]: Phil Bruner
Swattie Survival Guide
Wed, December 4, 2024
[ Wed, Dec 04th 2024 ]: Phil Bruner
California News
[ Wed, Dec 04th 2024 ]: Phil Bruner
President Joe Biden
Tue, December 3, 2024
[ Tue, Dec 03rd 2024 ]: Phil Bruner
The 40 Best Games of 2024
[ Tue, Dec 03rd 2024 ]: Phil Bruner
Boku No Roblox Codes
[ Tue, Dec 03rd 2024 ]: Phil Bruner
Yonhap News Agency
[ Tue, Dec 03rd 2024 ]: Phil Bruner
Beds, Herts & Bucks
[ Tue, Dec 03rd 2024 ]: Phil Bruner
Transfer news and rumors
Mon, December 2, 2024
[ Mon, Dec 02nd 2024 ]: Phil Bruner
Watch Samaa News Live
[ Mon, Dec 02nd 2024 ]: Phil Bruner
UK Celebrity News
[ Mon, Dec 02nd 2024 ]: Phil Bruner
The 100 Best Albums of 2024
[ Mon, Dec 02nd 2024 ]: Phil Bruner
From the Newspaper
[ Mon, Dec 02nd 2024 ]: Phil Bruner
South Australia
[ Mon, Dec 02nd 2024 ]: Phil Bruner
Whanganui Chronicle
Sun, December 1, 2024
[ Sun, Dec 01st 2024 ]: Phil Bruner
Wildlife Oddities of the Week
Sat, November 30, 2024
Fri, November 29, 2024
[ Fri, Nov 29th 2024 ]: Phil Bruner
Hotels and Resorts News
[ Fri, Nov 29th 2024 ]: Phil Bruner
The Best Jokes of 2024
Thu, November 28, 2024
[ Thu, Nov 28th 2024 ]: Phil Bruner
Climate and Environment
[ Thu, Nov 28th 2024 ]: Phil Bruner
December 2024 Issue
Wed, November 27, 2024
[ Wed, Nov 27th 2024 ]: Phil Bruner
Decoding Gen Z's content diet
Tue, November 26, 2024
[ Tue, Nov 26th 2024 ]: Phil Bruner
Illustrated Humor in the News
[ Tue, Nov 26th 2024 ]: Phil Bruner
World News
[ Tue, Nov 26th 2024 ]: Phil Bruner
Alexandra Petri
Mon, November 25, 2024
[ Mon, Nov 25th 2024 ]: Phil Bruner
All Kent news
Sun, November 24, 2024
Mon, December 15, 2008
[ Mon, Dec 15th 2008 ]: Market Wire
fasdfasddva s gfg h

VentriPoint 3D Heart Analysis System Approved for Pulmonary Arterial Hypertension in Canada

  Copy link into your clipboard //health-fitness.news-articles.net/content/2012/ .. r-pulmonary-arterial-hypertension-in-canada.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

May 04, 2012 07:00 ET

VentriPoint 3D Heart Analysis System Approved for Pulmonary Arterial Hypertension in Canada

VentriPoint to Market PAH Application in Canada

SEATTLE, WASHINGTON--(Marketwire - May 4, 2012) -

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

VentriPoint Diagnostics Ltd. ("VentriPoint" or the "Corporation") (TSX VENTURE:VPT) (OTCQX:VPTDF) is pleased to announce that it has received approval from Health Canada for VentriPoint's new Pulmonary Arterial Hypertension ("PAH") application for the VentriPoint Medical System™ ("VMS™").

The VMS™ is easier and more convenient than Magnetic Resonance Imaging (MRI) and safer than invasive arterial catheterization, which are two standard methods to monitor PAH patients. The PAH application enables repeated monitoring of the right ventricle and will assist in making sure PAH patients receive appropriate treatment in a timely manner.

"Many Canadian cardiologists have been inquiring about when the PAH application would be available in Canada. I am very pleased that we can now respond to growing demand in the Canadian market", said Dr. George Adams, President and CEO of VentriPoint.

It is estimated that 10,000 Canadians have been diagnosed with PAH and many more people are in the early stages and undetected. There are 18 specialized clinical centres in Canada and numerous smaller clinics to treat these patients. VentriPoint intends to approach all of these centres to offer the VMS™ PAH application.

VentriPoint announced on March 29, 2012 that it had received approval to market its PAH application in Europe. As a result, VentriPoint's European sales team has been taking orders and installing VMS™ heart analysis systems across the continent. The Company also announced on May 2, 2012 that it has initiated its clinical trial to secure US FDA approval to market its PAH application in the United States.

The Corporation also announces that, further to its press release of May 1, 2012 regarding its previously announced private placement of units, in the second closing of the private placement the Corporation may pay a commission of up to 10% of the gross proceeds from the sale of units either in cash or by the issuance of units, as well as a number of agent's options that is up to 10% of the number of units sold pursuant to the private placement, all subject to TSX Venture Exchange approval and compliance with applicable securities laws.

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leadingcause of death in developed countries. Management believes the VMS™ is the first cost-effective andaccurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the firstapplication in a suite of applications for all major heart diseases including pulmonary hypertension,cardiovascular disease and heart failure, which management believes has a multibillion-dollar marketpotential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™heart analysis system and VentriPoint is pursuing the US-FDA approval through the 510(k) process.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are nothistorical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect acurrent view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. These forward-looking statements are made as of the date of this press release and, other than as required by applicable securities laws, the Corporation does not assume any obligation to update or revise them to reflect newevents or circumstances. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

The common shares of the Corporation have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold in the United States or to "U.S. persons," as such term is defined under Regulation S promulgated under the U.S. Securities Act, absent registration under such laws or pursuant to an exemption from registration therefrom.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined inthe policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.